WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407158
Description: BG45 is a potent and selective HDAC3 inhibitor inhibitor with selectivity for HDAC3 (IC50 = 289 nM) over HDAC1, 2. BG45 did not inihibit HDAC6. BG45 signigicantly inhibited tumor growth in a mouse model of multiple myeloma either alone and synergistically in combination with bortezomib. HDAC3 represents a promising therapeutic target, and validate a prototype novel HDAC3 inhibitor BG45 in MM.
MedKoo Cat#: 407158
Chemical Formula: C11H10N4O
Exact Mass: 214.08546
Molecular Weight: 214.23
Elemental Analysis: C, 61.67; H, 4.71; N, 26.15; O, 7.47
Synonym: BG45; BG-45; BG 45.
IUPAC/Chemical Name: N-(2-Aminophenyl)pyrazine-2-carboxamide
InChi Key: LMWPVSNHKACEKW-UHFFFAOYSA-N
InChi Code: InChI=1S/C11H10N4O/c12-8-3-1-2-4-9(8)15-11(16)10-7-13-5-6-14-10/h1-7H,12H2,(H,15,16)
SMILES Code: O=C(C1=NC=CN=C1)NC2=CC=CC=C2N
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 214.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura
N, Ohguchi H, Cottini F, Jakubikova J, Munshi NC, Haggarty SJ, Richardson PG,
Hideshima T, Anderson KC. Histone deacetylase 3 as a novel therapeutic target in
multiple myeloma. Leukemia. 2014 Mar;28(3):680-9. doi: 10.1038/leu.2013.231. Epub
2013 Aug 5. PubMed PMID: 23913134; PubMed Central PMCID: PMC4165599.